Floatz logo

egf816

Triple Negative Breast Cancer (TNBC)

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
73/ 100

Competitive context

39 Active assets in the Triple Negative Breast Cancer (TNBC) cohort.

Asset / SponsorPhaseRating
DALPICICLIB ISETIONATE
Fudan University
Phase 3B
Shr-A1811
Fudan University
Phase 3B
IERAMILIMAB
Novartis Pharmaceuticals
Phase 2B
b013
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3CCC
Tuvonralimab
Harbin Medical University
Phase 2/3CCC

View all 50 →

Same molecule, other indications

egf816 is also rated in:

Carcinoma, Non-Small-Cell LungDormant
CCC
Indicative ·
52 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →